# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:INSM) with a Buy and maintains $83 price target.
—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Plac...
HC Wainwright & Co. analyst Andrew Fein reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $70 price target.
Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $68 to $88.
B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $62 to $83.
Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $...
Cantor Fitzgerald analyst Jennifer Kim reiterates Insmed (NASDAQ:INSM) with a Overweight.